103 related articles for article (PubMed ID: 1447706)
21. Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
Jung D; Lin L; Jiao H; Cai X; Duan JX; Matteucci M
Cancer Chemother Pharmacol; 2012 Mar; 69(3):643-54. PubMed ID: 21964906
[TBL] [Abstract][Full Text] [Related]
22. Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 5th communication: isolation and identification of metabolites of imidapril in rats, dogs, and monkeys.
Yamada Y; Ohashi R; Sugawara Y; Otsuka M; Takaiti O
Arzneimittelforschung; 1992 Apr; 42(4):490-8. PubMed ID: 1642672
[TBL] [Abstract][Full Text] [Related]
23. Physiological disposition of CGS 16617 in rat, dog, and man.
Egger H; Kochak G; Robertson P; Iannucci R; Rufino FA; Stancato F
Drug Metab Dispos; 1989; 17(6):669-72. PubMed ID: 2575505
[TBL] [Abstract][Full Text] [Related]
24. Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 1st communication: absorption, pharmacokinetics and excretion in rats and dogs.
Yamada Y; Endo M; Kohno M; Otsuka M; Takaiti O
Arzneimittelforschung; 1992 Apr; 42(4):457-65. PubMed ID: 1642668
[TBL] [Abstract][Full Text] [Related]
25. Plasma concentrations of an angiotensin-converting enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, after repeated administrations of benazepril in dogs with experimental kidney impairment.
Kitagawa H; Eguchi T; Kitoh K; Ohba Y; Kondo M; Nakano M; Sasaki Y
J Vet Med Sci; 2000 Feb; 62(2):179-85. PubMed ID: 10720188
[TBL] [Abstract][Full Text] [Related]
26. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs.
Toutain PL; Lefebvre HP; Laroute V
J Pharmacol Exp Ther; 2000 Mar; 292(3):1094-103. PubMed ID: 10688628
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of RU44403, an active form of newly developed angiotensin-converting enzyme inhibitor (RU44570) in the rat.
Hirayama M; Kurihara A; Manabe T; Hasegawa Y
Drug Metab Dispos; 1994; 22(4):601-6. PubMed ID: 7956736
[TBL] [Abstract][Full Text] [Related]
28. Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog.
Nordström M; Abrahamsson T; Ervik M; Forshult E; Regårdh CG
J Pharmacol Exp Ther; 1993 Jul; 266(1):147-52. PubMed ID: 8331554
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamic dependent disposition of the angiotensin converting enzyme inhibitor, libenzapril.
Kochak GM; Choi RL; deSilva JK; Reydel-Bax P
J Clin Pharmacol; 1990 Feb; 30(2):138-43. PubMed ID: 2312764
[TBL] [Abstract][Full Text] [Related]
30. Sites of first-pass bioactivation (hydrolysis) of orally administered zofenopril calcium in dogs.
Morrison RA; Burkett DE; Arnold ME; D'Arienzo CJ; Weinstein SH
Pharm Res; 1991 Mar; 8(3):370-5. PubMed ID: 2052527
[TBL] [Abstract][Full Text] [Related]
31. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach.
Toutain PL; Lefebvre HP; King JN
J Pharmacol Exp Ther; 2000 Mar; 292(3):1087-93. PubMed ID: 10688627
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats.
King JN; Maurer M; Toutain PL
J Vet Pharmacol Ther; 2003 Jun; 26(3):213-24. PubMed ID: 12755906
[TBL] [Abstract][Full Text] [Related]
33. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
Fukano Y; Kawazu K
Drug Metab Dispos; 2009 Aug; 37(8):1622-34. PubMed ID: 19477946
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride.
Friehe H; Ney P
Arzneimittelforschung; 1997 Feb; 47(2):132-44. PubMed ID: 9079232
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency.
Nakashima M; Yamamoto J; Shibata M; Uematsu T; Shinjo H; Akahori T; Shioya H; Sugiyama K; Kawahara Y
Eur J Clin Pharmacol; 1992; 43(6):657-9. PubMed ID: 1493850
[TBL] [Abstract][Full Text] [Related]
37. Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys.
Lin CC; Luu T; Lourenco D; Yeh LT; Lau JY
J Antimicrob Chemother; 2003 Jan; 51(1):93-9. PubMed ID: 12493792
[TBL] [Abstract][Full Text] [Related]
38. Disposition of zofenopril calcium in healthy subjects.
Singhvi SM; Foley JE; Willard DA; Morrison RA
J Pharm Sci; 1990 Nov; 79(11):970-3. PubMed ID: 2292772
[TBL] [Abstract][Full Text] [Related]
39. Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats.
Gardiner SM; Kemp PA; Brunner-Ferber F; Bennett T
Br J Pharmacol; 1997 Dec; 122(8):1687-93. PubMed ID: 9422815
[TBL] [Abstract][Full Text] [Related]
40. Species differences in the biotransformation of an alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist: the effects of distinct glucuronide metabolites on overall compound disposition.
Shaffer CL; Gunduz M; Ryder TF; O'Connell TN
Drug Metab Dispos; 2010 Feb; 38(2):292-301. PubMed ID: 19910512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
